HIGHLIGHTS OF PRESCRIBING INFORMATION
These highlights do not include all the information needed to use CISATRACURIUM BESYLATE INJECTION safely and effectively. See full prescribing information for CISATRACURIUM BESYLATE INJECTION.
CISATRACURIUM BESYLATE injection, for intravenous use
Initial U.S. Approval: 1995
RECENT MAJOR CHANGES
INDICATIONS AND USAGE
Cisatracurium Besylate Injection is a nondepolarizing neuromuscular blocker indicated:
Limitations of Use:
Cisatracurium Besylate Injection is not recommended for rapid sequence endotracheal intubation due to the time required for its onset of action. (1)
DOSAGE AND ADMINISTRATION
DOSAGE FORMS AND STRENGTHS
WARNINGS AND PRECAUTIONS
The most common adverse reactions (0.1% to 0.4%) were bradycardia, hypotension, flushing, bronchospasm, and rash. (6.1)
To report SUSPECTED ADVERSE REACTIONS, contact Hospira, Inc. at 1-800-441-4100 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
USE IN SPECIFIC POPULATIONS
Patients with Hemiparesis or Paraparesis: Perform neuromuscular monitoring on non-paretic limb. (8.9)
See 17 for PATIENT COUNSELING INFORMATION.
If you provide additional keywords, you may be able to browse through our database of Scientific Response Documents.